NASDAQ: ITCI - Intra-Cellular Therapies, Inc.

Yield per half year: +25.22%
Sector: Healthcare

Share chart Intra-Cellular Therapies, Inc.


About

Intra-Cellular Therapies, Inc., биофармацевтическая компания, разрабатывает новые препараты для лечения психоневрологических и неврологических заболеваний и других заболеваний центральной нервной системы (ЦНС) в США. Компания разрабатывает свой ведущий кандидат на лекарство CAPLYTA для лечения шизофрении, биполярного расстройства, поведенческих нарушений, связанных с деменцией, аутизмом и другими заболеваниями ЦНС.

More details
Также разрабатывается ITI-002, который ингибирует фермент фосфодиэстеразу типа 1; ITI-214 для болезни Паркинсона; и ITI-333 для расстройств, связанных с употреблением психоактивных веществ, боли и сопутствующих психических заболеваний, включая депрессию и тревогу. Головной офис Intra-Cellular Therapies, Inc. находится в Нью-Йорке, штат Нью-Йорк.


Main settings

P/S 28379.29
P/BV 2.05
EV/EBITDA -3.67
EBITDA -0.1623
Цена ао 70.26
Сайт https://www.intracellulartherapies.com
Число акций ао 0.09405 млрд
Выручка 6.1E-5
Див.доход ао 0
ISIN US46116X1019
Change price per day: -3.19% (72.73)
Change price per week: +2.68% (68.57)
Change price per month: +6.1% (66.36)
Change price per 3 month: +34.52% (52.34)
Change price per half year: +25.22% (56.23)
Change price per year: +40.71% (50.04)
Change price per 3 year: +126.91% (31.03)
Change price per 5 year: +362.01% (15.24)
Change price per year to date: -0.0993% (70.48)


All parameters ⇨

Grade

Underestimation

Title Value Grade
P/S 28379.29 1
P/BV 2.05 1
P/E 0 0
EV/EBITDA -3.67 0
Total:

Efficiency

Title Value Grade
ROA, % -41.18 0
ROE, % -47.72 0
Total:

Dividends

Title Value Grade
Div yield, % 0 0
DSI 0 0
Total:

Debt

Title Value Grade
Debt/EBITDA -0.0759 10
Total:

Growth impulse

Title Value Grade
Profit growth, % 21.71 4
Share price growth, % 48.07 10
Dividend growth, % 0 0
Total:

Insider trading

Transaction date Date of disclosure Insider Type Price Volume Quantity Share before, % Share after, % Document
11.01.2024 12.01.2024 Halstead Michael
EVP and General Counsel
Sale 66.83 3 341 500 50000 0 -0.06 link
11.01.2024 12.01.2024 Halstead Michael
EVP and General Counsel
Buy 13.6 680 000 50000 0 0.06 link
28.03.2023 30.03.2023 Neumann Mark
EVP, Chief Commercial Officer
Sale 54.31 847 453 15604 0 -0.02 link
13.03.2023 13.03.2023 Mates Sharon
Chairman, President & CEO
Sale 44.99 925 219 20565 0 -0.03 link
13.03.2023 13.03.2023 Mates Sharon
Chairman, President & CEO
Buy 3.26 65 200 20000 0 0.02 link
13.03.2023 13.03.2023 Hineline Lawrence J.
SVP of Finance CFO
Sale 44.93 250 799 5582 0 -0.01 link
13.03.2023 13.03.2023 Halstead Michael
EVP and General Counsel
Sale 44.94 330 039 7344 0 -0.01 link
13.03.2023 13.03.2023 Neumann Mark
EVP, Chief Commercial Officer
Sale 44.98 169 035 3758 0 0 link
13.03.2023 13.03.2023 Durgam Suresh K.
EVP, Chief Medical Officer
Sale 45.04 330 774 7344 0 -0.01 link
10.03.2023 13.03.2023 Mates Sharon
Chairman, President & CEO
Sale 43.15 1 802 380 41770 0 -0.05 link
10.03.2023 13.03.2023 Hineline Lawrence J.
SVP of Finance CFO
Sale 43.06 674 449 15663 0 -0.02 link
10.03.2023 13.03.2023 Halstead Michael
EVP and General Counsel
Sale 43.1 720 115 16708 0 -0.02 link
10.03.2023 13.03.2023 Neumann Mark
EVP, Chief Commercial Officer
Sale 43.34 370 557 8550 0 -0.01 link
21.09.2022 23.09.2022 Hineline Lawrence J.
SVP of Finance CFO
Sale 45.63 2 973 430 65164 0 -0.08 link
21.09.2022 23.09.2022 Hineline Lawrence J.
SVP of Finance CFO
Buy 15.47 1 008 090 65164 0 0.08 link
04.03.2022 04.03.2022 Durgam Suresh K.
Chief Medical Officer
Sale 55.52 214 307 3860 0 0 link
02.03.2022 04.03.2022 Durgam Suresh K.
Chief Medical Officer
Sale 56.98 238 005 4177 0 -0.01 link

Main owners

Institutions Volume Share, %
FMR, LLC 10979710 11.41
Vanguard Group Inc 8539725 8.87
Blackrock Inc. 7514851 7.81
Wasatch Advisors LP 3803139 3.95
Bellevue Group AG 3170250 3.29
Deep Track Capital, LP 2600000 2.7
State Street Corporation 2135435 2.22
JP Morgan Chase & Company 2063802 2.14
Invesco Ltd. 1935382 2.01
Geode Capital Management, LLC 1911022 1.99

Contained in ETF

Similar companies



Company management

Head Job title Payment Year of birth
Mr. Michael I. Halstead J.D. Executive VP, General Counsel & Secretary 983.65k 1973 (51 year)
Dr. Suresh K. Durgam M.D. Executive VP & Chief Medical Officer 961.84k 1969 (55 years)
Mr. Mark Neumann EVP & Chief Commercial Officer 998.36k 1963 (61 year)
Mr. Juan Fernando Sanchez Vice President of Corporate Communications & Investor Relations 296.75k 1971 (53 years)
Ms. Karen Patruno Sheehy Esq. Senior VP & Chief Compliance Officer N/A 1962 (62 years)
Dr. Michael Olchaskey Senior VP & Head of Regulatory Affairs N/A
Mr. John A. Bardi Senior VP of Market Access, Policy & Government Affairs N/A
Dr. Robert E. Davis Ph.D. Senior VP & Chief Scientific Officer 646.12k 1951 (73 years)
Dr. Sharon Mates Ph.D. Co-Founder, Chairman, CEO & President 2.23M 1953 (71 year)
Mr. Lawrence J. Hineline CPA Senior VP of Finance, CFO, Treasurer & Assistant Secretary 820.53k 1956 (68 years)

About company

Address: United States, New York, NY , 430 East 29th Street - open in Google maps, open in Yandex maps
Website: https://www.intracellulartherapies.com
Phone: +646 440 9333